In this episode of The Cancer SIGNAL, Nima Nabavizadeh, MD, an associate professor of radiation medicine at Oregon Health & Science University (OHSU) and the chief medical officer at the Cancer Early Detection Advanced Research Center (CEDAR) at OHSU, joins host Susanna Quinn to share the results from the groundbreaking GRAIL PATHFINDER 2 clinical trial unveiled at the European Society for Medical Oncology (ESMO 2025) Congress. As the principal investigator for the trial, which examined the safety and performance of the Galleri multi-cancer early detection test, Dr. Nabavizadeh discusses why the findings are pivotal for patients and could potentially redefine early cancer detection.

Watch the full episode on YouTube: https://youtu.be/owhDC8vH1hw

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

See Important Safety Information: http://bit.ly/33m8pFa

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

In this episode of The Cancer SIGNAL, Tad Carper, Senior VP of Communications for the Dallas Cowboys, shares how a multi-cancer early detection (MCED) screening unexpectedly revealed a cancer signal for head and neck cancer—despite experiencing no symptoms. The test, sponsored for the team's assistant coaches by quarterback Dak Prescott's foundation, Faith Fight Finish, was the first step toward Tad's stage two cancer diagnosis. Tad reflects on the emotional and mental impact of his diagnosis, the importance of early detection, and how the experience reshaped his values—deepening his appreciation for life, relationships, and the power of proactive health care. His story highlights the critical role of accessibility, awareness, and advocacy in cancer detection, and his commitment to "paying it forward" by helping others take early action in their own health journeys.

Watch the full episode on YouTube: https://www.youtube.com/watch?v=WuManHvHtS4

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider–recommended screening tests.

See Important Safety Information: http://bit.ly/33m8pFa

The overall sensitivity in study participants with head and neck cancer was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV).

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

At a semiannual primary care visit, Jack's doctor mentioned multi-cancer early detection (MCED) testing. Though Jack wasn't experiencing symptoms, and has no family history of cancer, he decided to take the test. Two Cancer Signal Detected results from MCED screening tests taken six months apart helped his care team determine the necessary diagnostics that confirmed an early-stage cancer diagnosis. Listen to Jack's story to learn more about the impact early cancer detection had on his life.

Watch the full episode on YouTube: https://youtu.be/p8fFVshFWJk

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

See Important Safety Information: http://bit.ly/33m8pFa

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.